SCHEMBL23674977

SCHEMBL23674977

CCc1cnccc1C(=O)Nc1ccc2c(c1)CC(C)(CC)C(=O)N2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 1/20 0.35
▸ BRD4 O60885 3/20 0.35
▸ KDR P35968 3/20 0.35
▸ MAP4K1 Q92918 2/20 0.35
▸ CREBBP Q92793 2/20 0.35
▸ FLT1 P17948 2/20 0.35
▸ CIT O14578 1/20 0.35
▸ MAP3K7 O43318 1/20 0.35
▸ RIPK2 O43353 1/20 0.35
▸ STK10 O94804 1/20 0.35
▸ MAP4K4 O95819 1/20 0.35
▸ ABL1 P00519 1/20 0.35
▸ EGFR P00533 1/20 0.35
▸ RAF1 P04049 1/20 0.35
▸ LCK P06239 1/20 0.35
▸ FYN P06241 1/20 0.35
▸ CSF1R P07333 1/20 0.35
▸ YES1 P07947 1/20 0.35
▸ LYN P07948 1/20 0.35
▸ RET P07949 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26089057 0.90 KDR (0.37) CRBNBRD4KDRMAP4K1FLT1
SCHEMBL26086646 0.87 OTUD7B (0.38) CRBNBRD4KDRMAP4K1LMNA
SCHEMBL31329494 0.82 MAP4K1 (0.51) CRBNMAP4K1
SCHEMBL21646064 0.82 MAP4K1 (0.51) CRBNMAP4K1
SCHEMBL31329495 0.82 MAP4K1 (0.51) CRBNMAP4K1
SCHEMBL26441299 0.80 BRD4 (0.57) CRBNBRD4ALK
SCHEMBL30100769 0.80 BRD4 (0.57) CRBNBRD4ALK
SCHEMBL30100774 0.79 BRD4 (0.39) CRBNBRD4KDRCREBBPLMNA
SCHEMBL26086551 0.79 BRD4 (0.39) CRBNBRD4KDRCREBBPLMNA
SCHEMBL21687088 0.79 CRBN (0.40) CRBNKDRMAP4K1LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230128402-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF THE TRUSTEES OF PRINCETON UNIVERSITY 2023-04-27 — — US disclosed
US-20230128402-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF THE TRUSTEES OF PRINCETON UNIVERSITY 2023-04-27 — — US disclosed
US-20230128402-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF THE TRUSTEES OF PRINCETON UNIVERSITY 2023-04-27 — — US disclosed
EP-4093400-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF The Trustees of Princeton University (US) 2022-11-30 — — EP disclosed
WO-2021151062-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF THE TRUSTEES OF PRINCETON UNIVERISTY (US) 2021-07-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230128402-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PAH, ALDH2, IDH2 CRBN 3317/4885BRD4 684/4885KDR 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback